CMECNECPE

This activity is supported by an educational grant from Akcea Therapeutics™ A Subsidiary of Ionis Pharmaceuticals, Inc.
Endorsed by: The National Lipid Association.

What You Need to Know About Familial Chylomicronemia Syndrome: Pathophysiology, Diagnosis, Management, and the Patient Perspective

What You Need to Know About Familial Chylomicronemia Syndrome: Pathophysiology, Diagnosis, Management, and the Patient Perspective

This activity is supported by an educational grant from Akcea Therapeutics™ A Subsidiary of Ionis Pharmaceuticals, Inc.
Endorsed by: The National Lipid Association.

Overview

Author(s)/Faculty: Michael H. Davidson, MD, FACC, FACP, FNLA
Source: Healio - Cardiology Education Lab
Type: LectureArticles/Items: 4
Release Date: 5/16/2017Expiration Date: 5/15/2018
Credit Type: CNE / CME / CPENumber of Credits: 1
Cost: FreeProvider: Vindico Medical Education

Familial chylomicronemia syndrome (FCS) is a rare genetic disease that leads to severe hypertriglyceridemia and recurrent episodes of acute pancreatitis. Due to its rarity and nonspecific signs and symptoms, FCS is often hard to diagnose. Currently, there is a lack of effective treatments for patients with FCS, although several agents in development show promise. Cardiologists play a crucial role in the diagnosis and ongoing care of patients with FCS; thus, it is critical to improve knowledge of this debilitating and potentially fatal disease. In this activity, a cardiologist will discuss the clinical manifestations of FCS, establishing the diagnosis, current unmet needs in treatment, and therapies on the horizon.

CE Information

page 1 of 7